<DOC>
	<DOCNO>NCT00337493</DOCNO>
	<brief_summary>This study determine , , allelic variant mycophenolic acid ( MPA ) metabolize enzymes , drug transporter drug target associate observed variation pharmacokinetic pharmacodynamic outcome observe CellCept usage . Patients participate study ML17225 eligible pharmacogenetic investigation , one additional blood sample take study . The anticipated time study treatment study ML17225 1-2 year , target sample size 500+ individual .</brief_summary>
	<brief_title>Pharmacogenetic Study CellCept ( Mycophenolate Mofetil ) Kidney Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>patient participate study ML17225 .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>